174 related articles for article (PubMed ID: 9765499)
1. Viral cell entry induced by cross-linked decay-accelerating factor.
Shafren DR
J Virol; 1998 Nov; 72(11):9407-12. PubMed ID: 9765499
[TBL] [Abstract][Full Text] [Related]
2. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.
Shafren DR; Dorahy DJ; Ingham RA; Burns GF; Barry RD
J Virol; 1997 Jun; 71(6):4736-43. PubMed ID: 9151867
[TBL] [Abstract][Full Text] [Related]
3. Cellular receptor interactions of C-cluster human group A coxsackieviruses.
Newcombe NG; Andersson P; Johansson ES; Au GG; Lindberg AM; Barry RD; Shafren DR
J Gen Virol; 2003 Nov; 84(Pt 11):3041-3050. PubMed ID: 14573809
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection.
Shafren DR; Dorahy DJ; Thorne RF; Barry RD
J Gen Virol; 2000 Apr; 81(Pt 4):889-94. PubMed ID: 10725413
[TBL] [Abstract][Full Text] [Related]
7. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451
[TBL] [Abstract][Full Text] [Related]
9. Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.
Shafren DR; Dorahy DJ; Thorne RF; Kinoshita T; Barry RD; Burns GF
J Immunol; 1998 Mar; 160(5):2318-23. PubMed ID: 9498772
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Goodfellow IG; Evans DJ; Blom AM; Kerrigan D; Miners JS; Morgan BP; Spiller OB
J Virol; 2005 Sep; 79(18):12016-24. PubMed ID: 16140777
[TBL] [Abstract][Full Text] [Related]
11. Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex.
He Y; Lin F; Chipman PR; Bator CM; Baker TS; Shoham M; Kuhn RJ; Medof ME; Rossmann MG
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10325-9. PubMed ID: 12119400
[TBL] [Abstract][Full Text] [Related]
12. Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAF-binding phenotype.
Powell RM; Ward T; Goodfellow I; Almond JW; Evans DJ
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3145-3152. PubMed ID: 10567645
[TBL] [Abstract][Full Text] [Related]
13. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21.
Shafren DR; Dorahy DJ; Greive SJ; Burns GF; Barry RD
J Virol; 1997 Jan; 71(1):785-9. PubMed ID: 8985417
[TBL] [Abstract][Full Text] [Related]
14. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.
Karnauchow TM; Dawe S; Lublin DM; Dimock K
J Virol; 1998 Nov; 72(11):9380-3. PubMed ID: 9765493
[TBL] [Abstract][Full Text] [Related]
15. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55).
Karnauchow TM; Tolson DL; Harrison BA; Altman E; Lublin DM; Dimock K
J Virol; 1996 Aug; 70(8):5143-52. PubMed ID: 8764022
[TBL] [Abstract][Full Text] [Related]
16. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A.
Williams P; Chaudhry Y; Goodfellow IG; Billington J; Powell R; Spiller OB; Evans DJ; Lea S
J Biol Chem; 2003 Mar; 278(12):10691-6. PubMed ID: 12499389
[TBL] [Abstract][Full Text] [Related]
17. Interactions of decay-accelerating factor (DAF) with haemagglutinating human enteroviruses: utilizing variation in primate DAF to map virus binding sites.
Williams DT; Chaudhry Y; Goodfellow IG; Lea S; Evans DJ
J Gen Virol; 2004 Mar; 85(Pt 3):731-738. PubMed ID: 14993659
[TBL] [Abstract][Full Text] [Related]
18. Differences in inhibition of replication between Coxsackie B4 virus strains in various cell lines by antibodies to some cell surface proteins.
Frisk G; Jansson K; Ericsson M; Diderholm H
Virus Res; 2001 Mar; 73(2):121-30. PubMed ID: 11172916
[TBL] [Abstract][Full Text] [Related]
19. A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells.
Shafren DR; Williams DT; Barry RD
J Virol; 1997 Dec; 71(12):9844-8. PubMed ID: 9371658
[TBL] [Abstract][Full Text] [Related]
20. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.
Milstone AM; Petrella J; Sanchez MD; Mahmud M; Whitbeck JC; Bergelson JM
J Virol; 2005 Jan; 79(1):655-60. PubMed ID: 15596863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
